Prestige Consumer Healthcare Posts $1.09B Revenue, $3.91 EPS, to Acquire LaCorium Health
Prestige Consumer Healthcare reported fiscal 2026 revenues of $1.09 billion and diluted EPS of $3.91, with fourth-quarter sales of $281.6 million and diluted EPS of $1.13. The company generated $246.4 million in free cash flow and agreed to acquire Australian skincare firm LaCorium Health while guiding 1–3% organic revenue and EPS growth.
1. Fiscal 2026 Results
Prestige Consumer Healthcare reported fiscal 2026 revenues of $1,088.7 million, a 4.3% decrease year-over-year, and diluted EPS of $3.91, down from $4.29. Fourth‐quarter revenues totaled $281.6 million, down 5.0%, with diluted EPS of $1.13 versus $1.00; free cash flow reached $246.4 million.
2. LaCorium Health Acquisition
The company agreed to acquire LaCorium Health, an Australian therapeutic skincare leader, expanding its portfolio into advanced skin therapeutics. The acquisition aims to leverage LaCorium’s established R&D and distribution network to drive growth in new markets.
3. Fiscal 2027 Outlook
For fiscal 2027, Prestige targets 1–3% organic revenue growth and 1–3% adjusted diluted EPS expansion, excluding acquisition impacts. This cautious outlook reflects ongoing supply constraints in Eye & Ear Care and anticipated benefits from recent strategic investments.